219 related articles for article (PubMed ID: 23091895)
1. Human epididymal protein 4 (HE4) is a novel biomarker and a promising prognostic factor in ovarian cancer patients.
Chudecka-Głaz A; Rzepka-Górska I; Wojciechowska I
Eur J Gynaecol Oncol; 2012; 33(4):382-90. PubMed ID: 23091895
[TBL] [Abstract][Full Text] [Related]
2. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
3. Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.
Furrer D; Grégoire J; Turcotte S; Plante M; Bachvarov D; Trudel D; Têtu B; Douville P; Bairati I
PLoS One; 2019; 14(6):e0218621. PubMed ID: 31220149
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
Ahmed AA; Abdou AM
Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
[TBL] [Abstract][Full Text] [Related]
5. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
Li W; Wang D
Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.
Schummer M; Drescher C; Forrest R; Gough S; Thorpe J; Hellström I; Hellström KE; Urban N
Gynecol Oncol; 2012 Apr; 125(1):65-9. PubMed ID: 22155417
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
8. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.
Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V
Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593
[TBL] [Abstract][Full Text] [Related]
9. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.
Zhang L; Chen Y; Wang K
Curr Probl Cancer; 2019 Apr; 43(2):135-144. PubMed ID: 30017407
[TBL] [Abstract][Full Text] [Related]
10. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.
Li Y; Wang ZC; Luo L; Mu CY; Xu J; Feng Q; Li SB; Gu B; Ma P; Lan T
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):604-610. PubMed ID: 32016961
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.
Dewan R; Dewan A; Jindal M; Bhardawaj M
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
13. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
[TBL] [Abstract][Full Text] [Related]
14. HE4--a novel promising serum marker in the diagnosis of ovarian carcinoma.
Langmár Z; Németh M; Vleskó G; Király M; Hornyák L; Bösze P
Eur J Gynaecol Oncol; 2011; 32(6):605-10. PubMed ID: 22335019
[TBL] [Abstract][Full Text] [Related]
15. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.
Zheng H; Gao Y
Int J Gynecol Cancer; 2012 Jul; 22(6):1000-5. PubMed ID: 22426406
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer.
Dikmen ZG; Colak A; Dogan P; Tuncer S; Akbiyik F
Eur J Gynaecol Oncol; 2015; 36(4):457-62. PubMed ID: 26390703
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.
Simmons AR; Baggerly K; Bast RC
Oncology (Williston Park); 2013 Jun; 27(6):548-56. PubMed ID: 23909069
[TBL] [Abstract][Full Text] [Related]
18. Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient's plasma - a prospective trial.
Hasenburg A; Eichkorn D; Vosshagen F; Obermayr E; Geroldinger A; Zeillinger R; Bossart M
BMC Cancer; 2021 Sep; 21(1):1037. PubMed ID: 34530759
[TBL] [Abstract][Full Text] [Related]
19. M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients.
Będkowska GE; Ławicki S; Gacuta E; Pawłowski P; Szmitkowski M
J Ovarian Res; 2015 May; 8():27. PubMed ID: 25935153
[TBL] [Abstract][Full Text] [Related]
20. [Diagnostic value of CA125, HE4 and Copenhagen Index in differentiating benign from malignant epithelial ovarian tumors].
Gong SP; Chen YN; Zhang YD; Yao W; Chen L; Liu SS; Wu H
Nan Fang Yi Ke Da Xue Xue Bao; 2017 May; 37(5):628-632. PubMed ID: 28539285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
